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Abstract:   
Background & Aims: Hepatitis C virus (HCV) is highly variable with 7 genotypes and 67 
subtypes characterized to date. HCV genotype (GT) and subtype, and presence of 
resistance associated substitutions (RASs) represent the key viral determinants for the 
selection of direct-acting antiviral (DAA) treatment regimens. However, currently 
available HCV genotyping assays have limitations in differentiating between HCV 
subtypes and RAS prevalence in different subtypes is largely undefined.  
 
Methods: In this study, we compared HCV GT and subtypes with INNO-LiPA 2.0 vs. 
amplicon sequencing among 8,945 patients from phase II/III clinical trials of DAAs. We 
also investigated global HCV molecular epidemiology in 12,615 patients. Subtype RAS 
prevalence was determined by population or deep sequencing, and phylogenetic 
analyses investigating subtype diversity were performed.  
 
Results: Though there was high concordance between INNO-LiPA and sequencing for 
GT determination, INNO-LiPA was insufficient for subtype determination for GT2, 3, 4, 
and 6. Sequencing provided subtype refinement for 42%, 10%, 81%, and 78% of GT2, 
3, 4, and 6 patients, respectively. GT discordance (GT2-GT1) was observed in 28 of 
950 (3%) GT2 patients, consistent with inter-genotype recombinants. Sequencing-
based analyses demonstrated variations in regional subtype prevalence, notably within 
GT2, 4 and 6. RAS prevalence varied by subtype, with the clinically relevant NS3 RAS 
Q80K found in GT1a, 5a and 6a and the NS5A RAS Y93H in GT1b, 3a, 4b, 4r and 7.  
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Conclusions: Together, these analyses provide an understanding of subtyping accuracy 
and RAS distribution that are crucial for the implementation of global HCV treatment 
strategies.  
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Lay Summary: 
The sequencing analyses performed on 12,615 patients with HCV infection investigated 
three main questions: (1) the concordance between NS5B amplicon sequencing and 
INNO-LiPA for HCV genotype (GT) determination; (2) the prevalence of HCV subtypes 
for each genotype around the world; and (3) the prevalence of resistance-associated 
substitutions (RASs) in different subtypes. Overall, there was high INNO-LiPA and 
sequencing concordance for GT determination, but subtype determination for GT2, 3, 4, 
and 6 needed sequencing refinements. Sequencing-based analyses demonstrated 
variations in regional subtype prevalence for some genotypes, notably within GT2, 4 
and 6, and RAS prevalence varied by subtype, with the clinically relevant NS3 RAS 
Q80K found in GT1a, 5a and 6a and the NS5A RAS Y93H in GT1b, 3a, 4b, 4r and 7. 
  
  
00078827 
 
Introduction: 
Hepatitis C virus (HCV) is a major human liver pathogen. It is estimated that 
>170 million people are affected worldwide and at risk for progressive liver disease and 
hepatocellular carcinoma (1, 2). HCV is classified into 7 genotypes and 67 subtypes, 
and displays ~30% divergence at the genotype level and ~15% divergence at the 
subtype level (3). HCV diversity is derived in part from its RNA-dependent RNA 
polymerase (RdRp) that lacks proofreading capability, recombination, genetic drift, and 
immune pressures on the virus (4). The treatment of HCV infection was revolutionized 
with the advent of highly effective direct-acting antiviral (DAA) treatment regimens that 
target HCV gene products, such as the NS5B RdRp, the NS5A phosphoprotein and 
NS3 protease (5).  
Similar to treatment with pegylated-interferon and ribavirin, selection of a DAA 
regimen, treatment duration and sustained virologic response (SVR) rate are dependent 
on HCV genotype (GT) and subtype (6-9). Previous investigations have shown that 
HCV GT distribution varies worldwide (10, 11), though less is known about HCV 
subtypes. HCV subtype sequences have been shown to cluster on phylogenetic trees 
based on region of origin (12-14). Potentially, the diversification of HCV in local 
epidemics could affect SVR rates if resistance associated substitutions (RASs) emerge.  
The prevalence of recombinant forms of HCV, detected in Eastern Europe and 
Russia (15-17), are not known on a global scale. Identification of recombinant 
sequences will inform the global prevalence of known recombinant viruses, like 
RF2k/1b, and potentially identify new recombinant forms in the population. It is 
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important to understand the prevalence of HCV endemic in different parts of the world 
as it could optimize the selection of therapeutic regimens and treatment durations.  
The presence of RASs for DAAs targeting NS3, NS5A and NS5B has not been 
systematically assessed across all HCV subtypes (18, 19). RASs vary at the subtype 
level (20) and could affect treatment outcome when present at baseline. Thus, in the 
absence of sequencing for each patient, the assessment of RASs in the context of HCV 
subtype should be considered for optimal DAA therapeutic regimens. 
The aim of this study was to investigate HCV epidemiology in 12,615 patient 
samples from 28 different countries across five geographic regions. As the accuracy of 
current genotyping methods may vary, we first compared subtype classification by 
INNO-LiPA, the current standard (21, 22), to sequencing of NS3/4A, NS5A and NS5B 
amplicons in a subset of 8,945 patient samples. We next investigated prevalence of 
HCV subtypes, and subtype-specific RASs across the different geographic regions.  
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Materials and Methods: 
Clinical samples 
The 12,615 patients analyzed provided written informed consent for enrollment in 
67 clinical studies run by Gilead Sciences (Foster City, CA) and Pharmasset (formerly 
Princeton, NJ). The studies and numbers of patients are outlined in Supplementary 
Table 1. Study protocols followed the ethical guidelines set in place by the 1975 
Declaration of Helsinki and were approved by the relevant institutional review board 
committees. All samples included in this analysis are baseline samples collected from 
treatment naïve and experienced patients. More than 95% of patients included were 
DAA-naïve. 
 
Genotyping using INNO-LiPA and amplicon sequencing 
The Siemens VERSANT HCV Genotype INNO-LiPA 2.0 Assay (Innogenetics, 
Ghent, Belgium) was performed by Covance (Indianapolis, IN; Singapore; Geneva, 
Switzerland), QLabs (Livingston, UK; Marietta, GA; Singapore) and Cenetron (Austin, 
TX). The genotype assignment from INNO-LiPA was used to select genotype-specific 
primers located outside of the gene target(s) that amplify the entire NS3/4A, NS5A, or 
NS5B regions in patient samples. Depending on the clinical trial, some patients had 
multiple gene targets amplified. Standard reverse transcription polymerase chain 
reaction (RT-PCR) was performed on patient plasma with HCV RNA >1000 IU/mL at 
DDL Diagnostic Laboratory (Rijswijk, The Netherlands). If amplification using genotype 
specific primers failed, a partial NS5B sequence was amplified using genotype 
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independent primers, allowing for sequence-based genotype/subtype classification of 
the sample. 
For deep sequencing, amplicons encoding the subject-derived NS3/4A, NS5A 
and NS5B were run using Illumina MiSeq v2 150 paired-end deep sequencing at DDL 
or WuXi AppTec (Shanghai, China). FASTQ files were split based on 100% matched 
barcodes. Contigs were generated from paired-end FASTQ files using VICUNA (Broad 
Institute, Cambridge, MA) and merged to create a de novo assembly sequence. All 
paired-end reads were merged using PEAR (Exelixis Lab, Heidelberg, Germany), 
chopped at the 3’ end when MAPQ<15, and filtered to remove reads <50 bases. The 
filtered reads were aligned to the de novo assembly sequence using MOSAIK v1.1.0017 
(Marth Lab, Boston, MA) to create a final assembly sequence. The aligned reads were 
translated in-frame and the resulting tabulated summary of variants from the final 
assembly was utilized to generate a consensus sequence. Mixtures were reported when 
present ≥15% of the viral population. Population sequences captured variants at 15% 
prevalence. 
NS3/4A, NS5A and NS5B consensus nucleotide and amino acid sequences were 
compared by the NCBI alignment tool BLAST (23) to a set of reference sequences to 
assign HCV genotype and subtype. A total of 170 NS3, 167 NS5A, and 169 NS5B 
reference sequences representing 7 genotypes and 67 subtypes were used for 
comparison. Each subtype was represented by 1-7 sequences in this reference set. A 
definitive genotype and subtype was indicated when its nucleotide and amino acid 
sequence had ≥85% homology to a reference sequence. The 85% threshold for the 
assignment of a subtype was designed to be conservative to allow subtypes to be 
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assigned and to prevent spurious assignments. The subtype with highest homology to a 
sequence at the nucleotide and amino acid level was reported for each sample. If 
multiple targets were sequenced, the subtype analysis results in multiple subtypes 
assigned to a patient sequence. In Table 1, a sample was labeled as “novel/mixed” if 
the closest reference sequence did not show at least ≥85% homology, if the genotype 
and subtype defined by nucleotide and amino acid homology were not identical, or if the 
subtype assignments were not identical between amplicons. In Table 2 and Figures 1, 
only NS5B was used to determine subtype. A sample was labeled “novel/mixed” if there 
was no subtype match with at least 85% homology, or if the top nucleotide and amino 
acid subtype hits was not identical. A sample was reported to be a GT2-GT1 
recombinant if the INNO-LiPA result indicated GT2, while NS3/4A, NS5A and/or NS5B 
sequencing indicated GT1 and full genome sequencing verified a recombination 
breakpoint in the virus (24). 
 
Concordance of INNO-LiPA and sequencing 
The genotype and subtype defined by INNO-LiPA and sequencing analyses were 
compared at baseline for 8,945 patients in Table 1, and categorized as concordant or 
discordant at the genotype level. At the subtype level, results were concordant when the 
subtype reported by INNO-LiPA matched sequencing, as in a result of GT2a by INNO-
LiPA and GT2a by sequencing. A result was categorized as refined when the correct 
genotype or subtype group was reported by INNO-LiPA but was not exact, as in a result 
of GT2 or GT2a/2c by INNO-LiPA and GT2a by sequencing. A result was discordant 
when an incorrect genotype or subtype was reported by INNO-LiPA as compared to 
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sequencing. A result of novel/mixed was reported when sequencing could not define the 
exact sample subtype.  
 
Global Prevalence of HCV subtypes 
The prevalence of HCV subtypes was estimated by using the HCV subtype 
determined by baseline NS5B sequencing for 12,615 patients and their associated 
country of origin in Table 2 and Figure 1. A virus was categorized as novel/mixed if the 
NS5B nucleotide and amino acid reference sequences determined by BLAST were not 
concordant. Subtype prevalence was calculated as: # of subtype in country/# of 
genotype in country. The region (and countries) reported are: North America (US, 
Canada and Puerto Rico), Europe (Great Britain, Ireland, Sweden, Germany, 
Netherlands, Belgium, France, Spain, Italy, Switzerland, Poland and Estonia), Asia 
(Russia, India, China, Hong Kong, Taiwan, Korea, Japan and Thailand), Oceania 
(Australia and New Zealand), and Africa (Egypt and South Africa). NS5B sequences 
representing genotypes 1c, 1e, 1g, 1h, 1l, 2i, 2j, 2k, 3g, 3i, 4c, 4f, 4k, 4l, 4n, 4o, 4r, 4t, 
6e, 6f, 6h, 6i, 6l, 6m, 6n, 6p, and 6q were deposited into GenBank (KY608611-
KY608718). 
 
RAS Prevalence by HCV subtype  
The subtype prevalence of HCV RASs was determined for NS3 (n=2,664), NS5A 
(n=7,893) and NS5B (n=11,074) in patients at baseline. Patients with DAA-experience 
were excluded from analysis. For each subtype, patient amplicon amino acid sequences 
were aligned and RAS positions analyzed for frequencies of amino acids present at the 
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noted location. RASs were detected with ≥15% prevalence in a patient. Of the RASs 
detected, those with ≥5% prevalence within the subtype population were reported in 
Tables 3-5. The majority and minority variants for each subtype were reported relative 
to the GT1a H77 reference amino acid at the indicated position.  
 
 
Phylogenetic Analysis 
Individual phylogenetic analyses were performed for NS5A and NS5B sequences 
from patients with GT3a and GT1b infection. Sequences were aligned using ClustalW 
(25). The NS5B GT3a phylogenetic tree included 351 sequences (Australia n=25, 
Canada n=47, Germany n=16, Spain n=13, Estonia n=3, France n=12, England n=41, 
India n=31, Italy n=12, Netherlands n=2, New Zealand n=19, Poland n=2, Puerto Rico 
n=2, Russia n=45, Sweden n=3, US n=78). The NS5B GT1b phylogenetic tree included 
621 sequences (Australia n=8, Belgium n=8, Canada n=3, England n=8, France n=17, 
Germany n=62, India n=47, Italy n=48, Ireland n=2, Japan n=70, Korea n=86, New 
Zealand n=39, Poland n=39, Puerto Rico n=7, Spain n=34, Taiwan n=67, USA n=76). 
Maximum likelihood phylogenetic trees were inferred using default parameters in GARLi 
(version 2.0), which optimizes the substitution model iteratively (26). The statistical 
significance of the branches was assessed by approximate likelihood-ratio test (aLRT) 
(27) using PhyML 3.0 (28) and a consensus tree was generated in PAUP (version 
4.0b10). Branches with p-values of <0.001 were considered supported. The 
phylogenetic trees were visualized using FigTree (version 1.3.1). A cluster is defined as 
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phylogenetically linked sequences which are separated from all other sequences by a 
significant branch.  
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Results: 
Comparison of genotype and subtype by INNO-LiPA and amplicon sequencing  
INNO-LiPA and amplicon sequencing were performed for 8,945 HCV-infected 
patients in order to provide HCV genotype (GT) and subtype. Based on INNO-LiPA 
results, 5,701 patients were GT1, 950 were GT2, 1,841 were GT3, 309 were GT4, 37 
were GT5 and 107 were GT6. There was a high level of concordance between these 
two approaches, as shown in Table 1. Greater than 99% agreement between INNO-
LiPA and amplicon sequencing was observed for GT1 (99.8%), GT3 (99.9%), GT4 
(99.7%), GT5 (100%) and GT6 (100%), whereas GT2 showed a concordance rate of 
96.9%. As a whole, 8,904/8,945 (99.5%) genotypes were concordant between INNO-
LiPA and amplicon sequencing. 
The GT2 concordance rate was ~3% lower than all other assayed genotypes. 29 
patient samples were presumably incorrectly typed by INNO-LiPA as GT2. 28/29 of 
these GT2 discordant samples were typed as GT1 by amplicon sequencing. 17/29 of 
these genotype discordant samples were investigated using full genome sequencing. In 
16/17 of these cases, the virus was an HCV recombinant between GT2 (5’UTR to NS2) 
and GT1 (NS3-3’UTR), with breakpoints present at the NS2-NS3 border, as previously 
described (29). 6 of these 16 GT2-GT1 recombinants were identified as the circulating 
RF2k/1b strain and were detected in patients from Belgium (2/6), the Netherlands (2/6), 
Spain (1/6), and the US (1/6). Another 6 of the 16 characterized GT2-GT1 recombinants 
were GT2b/1a recombinants and all were found in the US. The remaining 4 GT2-GT1 
recombinants were GT2b/1b recombinants found in the US (3/4) and Puerto Rico (1/4). 
12 of these 16 GT2-GT1 recombinants were characterized previously (29). Of interest, 
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the remaining characterized discordant GT2 sample (1/17) was identified to be GT7 
(30).  
Genotype discordant samples classified as GT1, 3 and 4 by INNO-LiPA were 
also investigated. Of the 10 patient samples found to be GT1 discordant, 8/10 where 
classified as GT6 by amplicon sequencing. Full genome sequencing analysis performed 
on 6/8 of these GT1 discordant samples corroborated that the viruses were GT6. There 
were only 2 patient samples that were either GT3 (n=1) or GT4 (n=1) discordant. In both 
cases, the virus was identified to be GT1 by amplicon sequencing. Similar to amplicon 
sequencing, the full genome sequencing analysis completed on the discordant GT3 
sample also defined the sample genotype as GT1. 
The concordance rate between INNO-LiPA and amplicon sequencing at the 
subtype level was more variable than at the genotype level. Subtyping for GT5 and GT1 
were the most successful, with 100% and 97.8% of the assigned subtypes corroborated 
by amplicon sequencing. The remaining genotypes had lower levels of subtype 
concordance. INNO-LiPA subtyping for GT2, 3, 4 and 6 had concordance rates of 
51.1%, 90.1%, 5.8% and 9.3% with amplicon sequencing and required refinement in 
41.5%, 9.5%, 81.2% and 77.6% of the samples, respectively. In these genotypes, one 
of the causes for INNO-LiPA refinement is due to the categorization of subtypes into 
groups, as in the subtype groups 2a/2c, 4a/4c/4d and 6c-l. Subtype discordance, where 
the subtype assignment was not captured by INNO-LiPA, was low in GT1 (0.6%), 3 
(0.3%) and 5 (0%). In contrast, GT2, 4 and 6 had higher discordance levels of 4.4%, 
10.7% and 8.4%, respectively. Furthermore, novel and/or mixed subtypes were 
observed at higher rates in GT2 (3.1%), 4 (2.3%) and 6 (4.7%). 
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Geographic distribution of HCV subtypes  
HCV subtype distribution for each genotype was analyzed in a data set of 12,615 
patients representing 7 HCV genotypes, 28 countries and 5 geographic regions, namely 
North America (n=7,891), Europe (n=2,166), Asia (n=977), Oceania (n=1,474) and 
Africa (n=107). NS5B sequencing was used to assign subtypes to all patients. 46 
previously characterized HCV subtypes from GT1-6 were captured in this analysis, 
identifying 7 GT1, 7 GT2, 6 GT3, 12 GT4, 1 GT5, and 13 GT6 subtypes. GT1-6 had a 
novel/mixed subtype category included due to the large number of sequences that did 
not match characterized strains. In addition, GT2-GT1 recombinant sequences and a 
genotype 7 sequence were surveyed. Thus, in total, 54 subtypes of HCV and their 
global distribution are shown by region in Table 2 and by country in Figure 1 and 
Supplementary Table 2. 
 In our sampling of GT1 (n=7,906), subtypes 1a and 1b were most prevalent 
across all countries. North America and Oceania was 76.4-78% subtype 1a and 21.8-
23.2% 1b, whereas Europe was 49.9% 1a and 48.4% 1b, and Asia was 95.6% 1b and 
4.1% 1a (Table 2). Interestingly, Poland, though included as a part of Europe, followed 
the Asian distribution and was 100% 1b. Novel/mixed GT1 sequences were detected in 
Great Britain (1.3%), France (0.8%) and India (4%), as well as in the US (0.1%) at a 
lower frequency. HCV GT2-GT1 recombinant strains (RCF2k-1b, GT2b-1a and GT2b-
1b), included under GT1, make up 0.2% of sampled strains in North America and 0.5% 
in Europe. 
Unlike GT1, the circulating subtypes of GT2 (n=1,408) vary widely. North 
America is predominantly subtype 2b (82.7%) and 2a (15.6%), while Asia is 
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predominantly subtype 2a (95.9%) followed by 2b (4.1%). Oceania is split between the 
three subtypes 2b (59.6%), 2a (35.4%) and 2c (5.1%). Interestingly, in Europe, there is 
no consensus in circulating GT2. Germany and Great Britain appear to mirror Oceania 
in being primarily subtypes 2b (55-63.3%) followed by 2a (13.3-25%) and 2c (10-15%), 
with the notable exception that 2i, 2j and 2k subtypes are detectable in the population. 
Italy has a unique GT2 subtype profile, with 100% 2c, a subtype which only appeared 
<34% in other locations. Most remarkably, a high proportion of circulating GT2 subtypes 
were novel/mixed in the Netherlands (60%), Belgium (33.3%) and France (28.3%). In 
addition, these countries had circulating subtypes 2a, 2b, 2c, 2i and 2k, giving them a 
divergent profile from other regions that were primarily 2a, 2b and/or 2c.  
 For GT3 (n=2,570), subtype 3a is most prevalent in North America (98.7%), 
Europe (98.9%) and Oceania (98.7%). However, the subtype breakdown in Asia is 
distinctive and is driven by the GT3 subtypes circulating in India. 55.9% of the 
individuals sampled in India were infected with subtype 3a, however subtype 3b 
(20.3%), 3g (6.8%), 3i (13.6%) and uncharacterized novel/mixed (3.4%) were present in 
the population as well. By contrast, Russia, the other country included as part of Asia, 
was 100% subtype 3a. 
 Similar to GT2, GT4 (n=526) subtype distribution varied widely, particularly in 
Europe. In our sampling, subtype 4a dominates North America (82.4%). Subtypes 4a 
(45.5%), 4d (45.5%) and 4n (9.1%) were observed to be circulating in Oceania. Africa, 
which in this study is represented by samples collected in Egypt, was primarily subtype 
4a (84.3%), followed by novel/mixed (9.8%), 4o (4.9%) and 4l (1%). It is notable that 
Egypt has novel/mixed GT4 subtypes as HCV spread in the population in the 1960-80s 
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during an anti-schistosomiasis campaign (31), presumably causing clonal infections. In 
Europe, the prevalence of GT4 subtypes changes per country, but is predominantly 4a 
(42.2%) and 4d (33.9%), similar to Oceania. However, Spain was the only country 
assayed to have circulating subtype 4b (72.7%). Belgium (23.1%), Germany (9.1%), 
Great Britain (5.6%) and France (3.4%) have high levels of circulating novel/mixed 
strains. Of note, GT2 novel/mixed strains were also observed in Belgium, Great Britain 
and France. 
 In GT5 (n=83), subtype 5a is the prevailing subtype in every tested country. The 
only exception to this observation is one patient in France who had a novel/mixed GT5 
strain detected. Even with a restricted sample population in GT6 (n=121), GT6 subtypes 
showed great diversity in all regions tested. The only characterized subtype to be 
sampled in North America (37.5%), Europe (33.3%), Asia (74.3%) and Oceania (33.3%) 
was 6a, but was present at varying frequency. Another commonality between regions 
was the detection of novel/mixed strains that occurred in the US (7.4%), France 
(33.3%), and New Zealand (8.3%).  
 
HCV subtype distribution of resistance-associated substitutions 
In our analysis of sequence data, a cutoff of 15% was used to call the presence 
of a polymorphism in a patient’s HCV consensus sequence. In order to determine the 
prevalence of RASs in different subtypes, we reported the presence of a RAS within a 
subtype when at least 5% of the patients sampled had the RAS present in their 
consensus sequence. NS3 (n=2,664), NS5A (n=7,893) and NS5B (n=11,074) 
sequences were analyzed for this RAS analysis. Baseline RAS frequencies in different 
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HCV subtypes are summarized for NS3 in Table 3. The NS3 RAS position Q80K has 
been shown to have high prevalence in GT1a as compared to GT1b (20) and testing for 
baseline Q80K is recommended prior to treatment with the NS3/4A inhibitor simeprevir 
due to reduced SVR rates (32). Our analysis corroborates a high baseline prevalence of 
Q80K in GT1a (36%), but not in GT1b (1.7%). Q80K was also detected in GT5a (100%) 
and GT6a (100%). 100% of HCV GT2 subtypes carried Q80G, however this is not 
considered a resistance-conferring substitution. V36L was found in the majority of all 
GT2, 3, 4 and 5 subtypes and in the 1 GT7 sequence assayed in our data set. Though 
not sampled extensively, GT1c (n=1; R155D, A156T, D168E), 1e (n=2; V36L, T54S, 
S122N) and 7 (n=1; V36L, V55A, D168Q) showed at least three NS3 RASs at baseline. 
Other major NS3 RASs found in HCV subtypes were D168E in GT5a (53%) and 6a 
(7%). 
Baseline NS5A RAS frequencies are shown by HCV subtype in Table 4. As 
compared to NS3, there was much higher diversity at RAS positions in NS5A. The 
NS5A RAS Y93H is associated with reduced NS5A DAA efficacy, with or without 
L31M/V/I in GT1b patients (33). Baseline Y93H was identified in GT1b (11%), 3a (6%), 
4b (50%), 4r (13%), and in the 1 GT7 patient. Other substitutions assayed at ≥50% at 
this position were Y93F (GT1g), Y93S (GT6f, 6m, 6n) and Y93T (GT6a, 6e, 6f, 6g, 6h, 
6l, 6o, 6p, 6q, 6r). The related NS5A RAS L31M/V/I, which increases resistance 
conferred by Y93H to NS5A inhibitors (34), was detected in the Y93H carrying subtypes 
GT1b (4%), 4b (100%) and 4r (25%), though not in GT3a or 7. L31M/V/I was sampled 
frequently across many GT2, 3 and 4 subtypes. Of note, all GT4r patients carried NS5A 
RASs at baseline. 3 of 8 GT4r patients carried triple NS5A RASs 
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(M28M/V+Q30R+L31M or M28M/V+Q30R+Y93H), 4 of 8 carried double NS5A RASs 
(M28M/V/I+Q30R) and 1 of 8 GT4r patients a single NS5A RAS (Q30R) at baseline.  
Baseline NS5B RASs were rare and are shown by HCV subtype in Table 5. The 
S282T mutation, which confers resistance against the NS5B inhibitor sofosbuvir (SOF) 
(35), was not found at any appreciable frequency in the assayed subtypes.  
  
Intra-subtype diversity 
Viral diversity within HCV is represented by a high number of characterized 
genotypes and subtypes, as is seen with GT4 and 6, but also by the variation within 
subtypes. Both GT1b and 3a are subtypes found at high frequency in different regions 
and, based only on subtyping, would not appear to be geographically divergent. 
However, localized epidemics could result in regional diversification of subtypes, 
identifiable through phylogenetic analysis by the formation of closely related sequence 
clusters.  
Remarkably, the majority of GT1b NS5B sequences (Figure 2) from the 47 
patients in India (red) formed two monophyletic clusters. The GT1b NS5B phylogenetic 
tree also revealed clustering of sequences from other countries. Japan (n=70), Korea 
(n=86) and Taiwan (n=67) (in orange and yellow) formed two major clusters in which 
very few sequences from other countries where intermixed. Of the 39 sequences from 
New Zealand (light blue), 27 formed a distinct cluster. As with GT1b, the majority of 
GT3a NS5B sequences from patients in India (red; 18/31) formed a significant 
monophyletic cluster (Figure 3). Clustering of GT3a sequences from patients in Russia 
(gray) was also observed. Unlike India, Russian GT3a sequences form three main 
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clusters and group with sequences from Europe and Oceania. Conversely, there is a 
high level of intermingling between GT1b and 3a sequences sampled from countries in 
North America (purple) and Europe (green). Similar clustering patterns were observed 
in GT1b and GT3a NS5A phylogenetic trees (data not shown), suggesting that the 
genetic differences observed were not specific for NS5B gene. The tight clusters of 
sequences could represent local HCV epidemics and diversification. However, since the 
sequences analyzed came from a limited number of patients recruited at clinical trial 
centers, more sampling will be needed in order to determine if the sequence clusters 
are representative of circulating virus in the aforementioned countries. 
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Discussion: 
A comprehensive analysis of genotyping/subtyping accuracy was performed in 
order to understand the limitations of standard subtyping methods. The current standard 
is the INNO-LiPA, a line probe reverse hybridization assay that uses probes to the 5’ 
untranslated region (UTR) and part of the core sequence to discern HCV type (12, 13). 
Assays that focus on a short part of the genome may not discern correct genotypes if 
there is high sequence homology, and are limited in identification of recombinant and/or 
novel strains (15, 16). Amplicon and full genome sequencing of HCV are alternate 
methods that provide greater resolution in the identification of genotype and subtype 
(16). However, it is not practical to perform sequencing in all clinical settings. Based on 
the geographic distribution of HCV, some regions may be impacted more by incorrect or 
incomplete identification by standard methods.  
We found high levels of concordance in genotype assignment between INNO-
LiPA and amplicon sequencing of NS3/4A, NS5A and/or NS5B, consistent with previous 
reports (29, 36). Overall, we observed 0.5% genotype discordance, with the highest 
proportion of discordant calls in GT2. Full genome sequencing analysis on GT2 
discordant samples confirmed that these discordant results primarily reflect the mis-
categorization of GT2-GT1 recombinant forms of HCV (16/17 cases).  
6/16 characterized GT2-GT1 recombinants were RF2k/1b. RF2k/1b is known to 
circulate in countries in Europe, with a noted high prevalence in Georgia, and was first 
described in a case from St. Petersburg, Russia (15-17). The sampled viruses had 
indistinguishable recombination breakpoints in NS2 from the original St. Petersburg 
RF2k/1b. Previous phylogenetic analysis (29) has indicated that these patients were 
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likely infected by the circulating RF2k/1b strain and are not the result of unique 
recombination events. Patients with RF2k/1b were sampled in Europe, including 
Belgium (n=2), the Netherlands (n=2) and Spain (n=1), and in the US (n=1). Belgium 
had its first cases of RF2k/1b reported in patients originating from Georgia and the 
Chechen Republic (37); however, the ethnic background of the two patients from 
Belgium identified in our study is unknown.  
All non-RF2k/1b characterized recombinants were sampled in North America, 
including 6 patients with recombinant GT2b/1a and 4 patients with GT2b/1b virus. 
Unlike the circulating RF2k/1b, there does not appear to be a prevalent circulating form 
of either recombinant GT2b/1a or 2b/1b. The GT2b/1a or 2b/1b patients did not 
unequivocally share identical recombination breakpoints. Phylogenetic analyses (29) 
suggest that unique recombination events generated these viruses in some cases.  
The majority of GT1 discordants were confirmed to be GT6 by full genome 
sequencing (6/8), indicating that the INNO-LiPA v2.0 still has difficulty in discerning 
between these two genotypes, though at a lower rate than the previous version (36, 38). 
The diversity and sequence complexity in GT6 subtypes may contribute to the 
continued problem in distinguishing GT1 and GT6, even with the presence of probes 
directed at the core. 
The overall level of refinement and discordance needed in subtyping was 12.3%, 
however this disproportionately affected GT2, 3, 4 and 6. Strikingly, the level of 
novel/mixed subtypes was also highest for GT2 (3.1%), 4 (2.3%) and 6 (4.7%). The 
subtype diversity within each genotype appeared to be directly correlated to the higher 
levels of discordancy and refinement needed. The patient sequences included under 
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novel/mixed were not fully characterized, but their occurrence in these genotypes 
indicates that their subtype diversity could be significantly under sampled.  
The global prevalence of subtypes corroborated the observation of high diversity 
in GT2, 4 and 6. The high number of circulating GT2, 4 and 6 subtypes contrasts with 
what is seen in GT1, 3 and 5, where 1-2 subtypes predominate. Subtype diversity and 
prevalence varied region, as has been shown with genotype prevalence (10, 11). 
Interestingly, France harbored novel/mixed strains of GT1 (n=3; 0.8%), 2 (n=13; 28.3%), 
4 (n=4; 3.4%), 5 (n=1; 1.8%) and 6 (n=1; 33.3%). The reason for the increased 
frequency of uncharacterized subtypes measured in France is unclear, though 
immigration patterns should be considered as a contributing factor and investigated 
using phylogeographic analyses. The subtype and RAS distributions determined are 
representative of the patients enrolled in clinical trials run at specific regional medical 
centers in primarily developed countries, and thus may not reflect the all of the global 
landscape. Migration of patients to the clinical trial centers may have impacted our 
reported subtype distributions as well. Greater sampling will be needed in order to 
determine global distribution.  
The RAS analysis revealed that NS5B DAA resistance is infrequent, but NS3 and 
NS5A DAA RASs are detected at higher frequencies in the population. The analyzed 
population excluded DAA-experienced patients. In NS5B, the presence of the NS5B 
RAS L159F was only detected in GT1b at 8% prevalence (Table 5). L159F is 
associated with a lower rate of SVR in only shorter duration (<24 week) regimens 
containing SOF with RBV, however not in combination regimens targeting both NS5A 
and NS5B, with PEG-IFN, or when using recommended treatment times (39). The 
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NS5B RAS S282T, the only RAS with demonstrated in-vitro resistance to SOF, was not 
detected in any GT at baseline.  
The NS5A variants at RAS position Y93 were detected in many of the subtypes 
sampled. The Y93H variant was found in GT1b (11%), GT3a (6%), GT4b (50%) and 
GT4r (13%). GT4r had a high prevalence of NS5A RASs in the 8 patients analyzed, with 
most patients carrying 2 NS5A RASs at baseline. In a study of lepidasvir (LDV)/SOF 
treatment for 12 weeks in GT4 infection, 2 of 3 patients with GT4r did not achieve SVR 
(40). The GT4r patient successfully treated with LDV/SOF had 2 NS5A RASs 
(M28I+Q30R) at baseline, similar to most GT4r patients in our analysis (50%). The two 
patients who failed therapy had 3 NS5A RASs (M28M/V+Q30R+L31M) at baseline. Due 
to the small sample size, it is unclear if failure is due to the higher number of NS5A 
RASs in those GT4r patients. The NS5A variants detected in GT1a and 1b this analysis 
corroborate results from a recent publication (41). 
NS3 RASs were found in multiple subtypes in the analyzed population. D168 
variants were detected in all GT3a, 3b, and 3i isolates (D168Q), 53% of GT5a (D168E) 
and 7% GT6a (D168E) isolates sampled, as well as in the single patients sampled 
representing GT1c (D168E) and GT7 (D168Q). Q80K, associated with resistance to 
simeprevir, was detected at a prevalence of 36% of GT1a patients, and Q80L was 
detected in the n=2 GT1l patients sampled. V36L, which confers resistance to telaprevir, 
was observed in almost all GT2-5 patients sampled. GT1c, 1e and 7 had triple 
combinations of NS3 RASs prevalent within the population studied. The use of 
combination DAA regimens, and not monotherapy, in these subtypes may lessen the 
impact of circulating RASs on treatment outcome. 
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Future work should focus on how HCV subtype prevalence changes amid 
ongoing cure treatments and how subtypes respond differently to current DAA 
regimens, especially in light of subtype-specific polymorphisms seen in our RAS 
analysis. Differences in regimen efficacy based on subtype would be appear to be most 
important for GT2, GT4 and GT6 and thus would affect countries in North and Central 
Africa, the Middle East and Asia more prominently. If subtypes within these genotypes 
are harder to treat, diagnosis and treatment optimization would be exacerbated by the 
lack of accurate subtyping using standard methods. Thus, continued surveillance is 
critical in order to develop the most effective strategies for HCV elimination worldwide. 
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Figure Legends:  
 
Figure 1. Subtype distributions of HCV genotypes 1-6 determined using 
sequencing-based analysis.  
The proportions of subtypes circulating for GT1 (A), GT2 (B), GT3 (C), GT4 (D), GT5 
(E), and GT6 (F) are plotted for each country sampled. The color key for different 
subtypes is shown to the right of each figure. The novel/mixed category refers to 
sequences assayed that did not sufficiently match a characterized subtype. Countries 
are organized by geographic region, moving left to right: North America, Europe, Asia, 
Oceania, and/or Africa.  
 
Figure 2. Maximum likelihood phylogenetic tree of genotype 1b NS5B sequences. 
621 GT1b sequences were included in the maximum-likelihood tree and branches with 
statistical significance (p<0.001) are noted with an asterisk. One significant cluster of 
sequences from India (red) contained 21/47 sequences and the other contained 11/47 
sequences. The two significant branches with sequences from Japan, Korea and 
Taiwan (yellow and orange) contained 223 sequences. 27 sequences from New 
Zealand (blue) formed a significant cluster. 
 
Figure 3. Maximum likelihood phylogenetic tree of genotype 3a NS5B sequences. 
351 sequences GT3a sequences were included in the maximum-likelihood tree and 
branches with statistical significance (p<0.001) are noted with an asterisk. 18/31 
sequences from India (red) formed a cluster and the 45 sequences from Russia (gray) 
formed three main clusters (Cluster 1 Russian sequences n=16, England n=1; Cluster 2 
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Russian sequences n=9; Cluster 3 Russian sequences n=19, Estonia n=3, Australia 
n=1). 
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Table 1. Summary of Concordant and Discordant Results by HCV Genotype and Subtype 
HCV 
Genotyp
e 
(by 
INNO-
LiPA, 
5’UTR 
and 
Core 
detectio
n) 
Patien
ts 
HCV Genotype  
(by sequencing NS3/4A, 
NS5A and/or NS5B) 
HCV Subtype 
(by sequencing NS3/4A, NS5A  
and/or NS5B) 
Concordant Discordant Concordant Refined 
Discordan
t 
Novel/mix
ed 
 
 n n % n % n % n % n % n % 
1 5701 5691 99.8% 10
a
 
0.2
% 
557
6 97.8% 80 1.4% 35 0.6% 10 
0.2
% 
2 950 921 96.9% 29b 3.1% 485 51.1% 
39
4 
41.5
% 42 4.4% 29 
3.1
% 
3 1841 1840 99.9% 1
c
 
0.1
% 
165
9 90.1% 
17
4 9.5% 6 0.3% 2 
0.1
% 
4 309 308 99.7% 1 0.3% 18 5.8% 
25
1 
81.2
% 33 
10.7
% 7 
2.3
% 
5 37 37 100.0% 0 
0.0
% 37 
100.0
% NA NA NA NA NA NA 
6 107 107 100.0% 0 
0.0
% 10 9.3% 83 
77.6
% 9 8.4% 5 
4.7
% 
Total 8945 8904 99.5% 41
d
 
0.5
% 
778
5 87.0% 
98
2 
11.0
% 
12
5 1.4% 53 
0.6
% 
 
Concordant: Genotype/subtype result from INNO-LiPA was an exact match to the genotype/subtype determined by 
sequencing. 
Discordant: Genotype/subtype result from INNO-LiPA did not match the genotype/subtype determined by 
sequencing. 
Refined: The category of genotype/subtype from INNO-LiPA (e.g.  4a/c/d or 6c-l) was correct but not as specific as 
the genotype/subtype determined by sequencing. 
Novel/mixed: The genotype/subtype could not be specifically determined by sequencing and was interpreted to 
indicate a novel or mixed subtype. 
 
a
 6/6 INNO-LiPA genotype 1 discordant samples tested by full genome sequencing were confirmed to be genotype 6. 
b
 16/17 INNO-LiPA genotype 2 discordant samples tested by full genome sequencing were confirmed to be genotype 
2/1 recombinants and 1/17 was confirmed to be genotype 7.  
c
 The INNO-LiPA genotype 3 discordant sample tested by full genome sequencing was confirmed to be genotype 1. 
d
 4/41 samples had inconclusive INNO-LiPA results and were additionally genotyped using TRUGENE HCV 5’NC kit 
(Siemens Healthcare Diagnostics).  
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Table 2. Prevalence of HCV Subtypes by Geographic Region  
 
Total  
(n=12,615) 
North America 
(n=7,891) 
Europe 
(n=2,166) 
Asia 
(n=977) 
Oceania 
(n=1,474) 
Africa 
(n=107) 
Subtype n % n % n % n % n % 
1a 4265 76.4 552 49.9 26 4.1 451 78.0 
  
1b 1295 23.2 536 48.4 612 95.6 126 21.8 
  
1c 2 0.0 0 0.0 0 0.0 0 0.0 
  
1e 0 0.0 5 0.5 0 0.0 0 0.0 
  
1g 1 0.0 0 0.0 0 0.0 1 0.2 
  
1h 1 0.0 1 0.1 0 0.0 0 0.0 
  
1l 2 0.0 3 0.3 0 0.0 0 0.0 
  
Genotype 1 Novel/mixed 4 0.1 5 0.5 2 0.3 0 0.0   
Recombinant 2/1* 11 0.2 5 0.5 0 0.0 0 0.0 
  
2a 148 15.5 26 16.3 35 35.4 35 33.3 
  
2b 787 82.7 43 26.9 59 59.6 64 61.0 
  
2c 5 0.5 54 33.8 5 5.1 6 5.7 
  
2d 0 0.0 1 0.6 0 0.0 0 0.0 
  
2i 2 0.2 10 6.3 0 0.0 0 0.0 
  
2j 1 0.1 1 0.6 0 0.0 0 0.0 
  
2k 1 0.1 3 1.9 0 0.0 0 0.0 
  
Genotype 2 Novel/mixed 8 0.8 22 13.8 0 0.0 0 0.0 
  
3a 1059 98.7 623 98.9 79 75.2 752 98.7 
  
3b 7 0.7 3 0.5 12 11.4 6 0.8 
  
3g 3 0.3 1 0.2 4 3.8 0 0.0 
  
3h 0 0.0 2 0.3 0.0 0.0 0 0.0 
  
3i 4 0.4 0 0.0 8.0 7.6 0 0.0 
  
3k 0 0.0 1 0.2 0 0.0 4 0.5 
  
Genotype 3 Novel/mixed 0 0.0 0 0.0 2 1.9 0 0.0 
  
4a 182 82.4 81 42.2 
  
5 45.5 86 84.3 
4b 0 0.0 10 5.2 
  
0 0.0 0 0.0 
4c 0 0.0 3 1.6 
  
0 0.0 0 0.0 
4d 8 3.6 65 33.9 
  
5 45.5 0 0.0 
4f 0 0.0 4 2.1 
  
0 0.0 0 0.0 
4k 2 0.9 1 0.5 
  
0 0.0 0 0.0 
4l 3 1.4 0 0.0 
  
0 0.0 1 1.0 
4m 1 0.5 1 0.5 
  
0 0.0 0 0.0 
4n 7 3.2 3 1.6 
  
1 9.1 0 0.0 
4o 13 5.9 6 3.1 
  
0 0.0 5 4.9 
4r 1 0.5 8 4.2 
  
0 0.0 0 0.0 
4t 0 0.0 1 0.5 
  
0 0.0 0 0.0 
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North America: US, Canada and Puerto Rico 
Europe: Great Britain, Ireland, Sweden, Germany, Netherlands, Belgium, France, Spain, Italy, Switzerland, Poland 
and Estonia 
Asia: Russia, India, China, Hong Kong, Taiwan, Korea, Japan and Thailand 
Oceania: Australia and New Zealand 
Africa: Egypt and South Africa 
Novel/mixed: The genotype/subtype could not be specifically determined by sequencing and was interpreted to 
indicate a novel or mixed subtype. 
 
*Excluded 13 putative GT2/1 recombinants not confirmed by full genome sequence.
Genotype 4 Novel/mixed 4 1.8 9 4.7 
  
0 0.0 10 9.8 
5a 8 100.0 69 98.6 
    
5 100.0 
Genotype 5 Novel/mixed 0 0.0 1 1.4 
    
0 0.0 
6a 21 37.5 2 33.3 26 74.3 8 33.3 
  
6e 18 32.1 0 0.0 0 0.0 5 20.8 
  
6f 0 0.0 0 0.0 1 2.9 0 0.0 
  
6g 0 0.0 0 0.0 5 14.3 0 0.0 
  
6h 3 5.4 0 0.0 0 0.0 0 0.0 
  
6i 0 0.0 0 0.0 1 2.9 0 0.0 
  
6l 5 8.9 1 16.7 0 0.0 2 8.3 
  
6m 1 1.8 0 0.0 0 0.0 2 8.3 
  
6n 1 1.8 1 16.7 2 5.7 0 0.0 
  
6o 1 1.8 0 0.0 0 0.0 0 0.0 
  
6p 0 0.0 0 0.0 0 0.0 2 8.3 
  
6q 2 3.6 1 16.7 0 0.0 2 8.3 
  
6r 0 0.0 0 0.0 0 0.0 1 4.2 
  
Genotype 6 Novel/mixed 4 7.1 1 16.7 0 0.0 2 8.3 
  
GT7 
  
1 100.0 
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Table 3. NS3 RASs in HCV GT1-7 Subtypes  
 
 
  NS3 RAS POSITIONa,b,c 
Subtype Patients (n)* V36
d
 Q41 T54 V55 Q80 S122 R155 A156 D168 
1a 1474 -e - - - Q (64%) K (36%) 
S (94%) 
G (8%) R (98%) - - 
1b 583 - - - - - S (87%) T (7%), G (6%), N (5%) - - - 
1c 1 NA NA NA NA NA NA D (100%) T (100%) E (100%) 
1e 2 L (100%) - S (100%) - - N (100%) - - - 
1g 0          
1h 0          
1l 2 - - - - L (100%) - - - - 
2k-1b 4 - - - - - S (50%) G (25%), N (25%) - - - 
2a 31 L (94%) M (6%) - - - G (100%) K (97%) - - - 
2b 59 L (100%) - - - G (100%) R (100%) - - - 
2c 10 L (100%) - - - G (100%) R (100%) - - - 
2d 0          
2e 0          
2i 2 L (100%) - - - G (100%) R (100%) - - - 
2j 1 L (100%) - - - G (100%) R (100%) - - - 
2k 0          
2r 0          
3a 383 L (100%) - - - - - - - Q (100%) 
3b 2 L (100%) - - - - - - - Q (100%) 
3g 0          
3h 0          
3i 1 L (100%) - - - - - - - Q (100%) 
3k 0          
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4a 50 L (100%) - - - - T (100%) - - - 
4b 0          
4c 1 L (100%) - - - - T (100%) - - - 
4d 12 L (100%) - - - - T (92%) S (8%) - - - 
4f 0          
4k 1 L (100%) - - - - T (100%) - - - 
4l 0          
4m 0          
4n 2 L (100%) - - - - T (100%) - - - 
4o 1 L (100%) - - - - T (100%) - - - 
4r 0          
4t 0          
5a 15 L (100%) - - - K (100%) A (53%) T (47%), G (7%), V (7%) - - 
D (60%)  
E (53%) 
6a 15 - - - - K (100%) N (100%) - - D (93%) E (7%) 
6d 0          
6e 11 - - - - - T (82%) A (18%), S (9%) - - - 
6f 0          
6g 0          
6h 0          
6k 0          
6l 3 - - - - - S (100%) N (33%) - - - 
6m 1 - - - - - T (100%) - - - 
6n 1 - - - - - - - - - 
6o 0          
6p 0          
6q 0          
6r 0          
7 1 L (100%) - - A (100%) D (100%) K (100%) - - Q (100%) 
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a RASs reported with ≥5% prevalence within each analyzed subtype population.  
b
 RASs detected with ≥15% abundance in patient virus sequence.  
c
 RASs carried by the majority of the subtype population (≥50% prevalence) are in bold. RASs held by a minority (<50%) of the subtype population are not in bold 
and are listed in order of prevalence. 
d
 Reference amino acid at RAS site based on GT1a H77 reference sequence is not associated with resistance. Any changes from this reference are shown.  
e
 Dash (-) indicates no change from reference and no minority substitutions detected in analysis. 
* Patient n represents all patients analyzed across all positions. Actual analyzed number may be lower depending upon position. 
NA = not available; a partial sequence did not overlap the analyzed RAS position. 
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Table 4. NS5A RASs in HCV GT1-7 Subtypes 
 
 
  NS5A RAS POSITIONa,b,c 
Subtype Patients (n)* K24
d
 M28 Q30 L31 P32 S38 H58 A92 Y93 
1a 3532 -e M (96%) V (6%) - - - - 
H (94%) 
P (6%) - - 
1b 1972 Q (97%) L (98%) R (92%) Q (9%) L (96%) - - 
P (93%) 
S (5%) - 
Y (96%) 
H (11%) 
1c 2 - V (100%) - - - - P (100%) - - 
1e 5 Q (60%) K (20%), R (20%) - 
Q (60%) 
L (20%), R (20%) 
L (60%) 
M (40%) - - P (100%) 
T (60%) 
A (20%), V (20%) - 
1g 2 R (50%) S (50%) L (100%) - - - - P (100%) - F (100%) 
1h 2 Q (100%) L (100%) R (100%) - - - P (100%) - - 
1l 3 G (67%) S (67%) - 
R (67%) 
Q (33%) M (100%) - - P (100%) - - 
2k-1b 4 Q (100%) L (100%) R (100%) - - - P (100%) V (75%) A (25%) - 
2a 106 T (80%) A (19%) F (95%) K (97%) M (97%) - - 
P (95%) 
S (6%) 
C (95%) 
S (5%) - 
2b 441 S (100%) L (98%) K (100%) L (67%) M (39%) - - 
P (96%) 
S (5%) C (100%)  - 
2c 27 S (100%) F (59%) C (41%) 
K (96%) 
R (11%) 
L (89%) 
M (11%) - - P (93%) C (100%) - 
2d 2 S (100%) L (100%) K (100%) L (50%) M (50%) - - P (100%) C (100%) - 
2e 2 S (100%) L (50%) F (50%) K (100%) 
L (50%) 
M (50%) - - P (100%) C (100%) - 
2i 11 S (100%) F (100%) K (100%) R (9%) M (100%) - - P (100%) C (100%) - 
2j 2 S (100%) F (100%) K (50%) R (50%) M (100%) - - P (100%) C (100%) - 
2k 9 S (100%) T (11%) 
L (67%) 
F (44%) 
K (89%) 
S (11%) 
M (67%) 
L (22%), I (11%) - - 
P (89%) 
S (11%) 
C (100%) 
S (11%) - 
2r 2 S (100%) L (50%) C (50%) K (100%) - - - P (100%) C (100%) - 
3a 1263 S (99%) - A (91%) K (5%) - - - P (97%) E (100%) 
Y (97%) 
H (6%) 
3b 25 S (92%) A (8%) - K (96%) 
M (92%) 
L (8%) - - P (100%) E (100%) - 
3g 5 A (60%) S (40%) - K (100%) 
M (80%) 
V (20%) - - P (100%) E (100%) - 
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3h 1 S (100%) - A (100%) - - - P (100%) E (100%) - 
3i 12 S (100%) - K (100%) R (8%) - - - P (100%) E (100%) - 
3k 3 G (100%) M (67%) L (33%) K (100%) M (100%) - - P (100%) E (100%) - 
4a 166 - L (82%) M (18%) 
L (87%) 
R (12%) M (100%) - - P (96%) - - 
4b 4 - L (50%) M (50%) 
S (50%) 
I (25%), L (25%) M (100%) - - 
P (50%) 
S (25%), T (25%) - 
H (50%) 
Y (50%) 
4c 3 - L (100%) R (100%) M (67%) L (33%) - - 
P(67%) 
T (33%) - - 
4d 66 - L (98%) R (98%) M (97%) L (5%) - - 
P (62%) 
T (30%), A (6%) - - 
4f 4 - L (100%) R (100%) M (100%) - - P (100%) - - 
4k 3 - L (100%) R (100%) L (67%) M (33%) - - P (100%) - - 
4l 1 - L (100%) R (100%) M (100%) - - P (100%) - - 
4m 1 - L (100%) S (100%) M (100%) - - P (100%) - - 
4n 9 - L (100%) R (100%) M (100%) - - T (78%) P (22%), N (11%) - - 
4o 12 - - T (92%) S (8%) 
M (92%) 
V (8%) - - P (100%) - - 
4r 8 - M (38%), V (38%),  I (13%), L (13%) R (100%) 
L (75%) 
M (25%) - - P (100%) - 
Y (100%) 
H (13%) 
4t 1 - L (100%) R (100%) M (100%) - - P (100%) - - 
5a 77 Q (100%) L (100%) - - - - P (97%) - - 
6a 55 Q (89%) K (9%), R (7%) 
L (65%) 
F (45%) R (100%) - - - T (96%) - T (98%) 
6d 2 - V (100%) A (100%) - - - P (100%) - T (100%) 
6e 24 K (83%) R (17%) 
V (75%) 
M (33%) S (96%) - - - P (96%) - 
T (96%) 
S (8%) 
6f 1 - M (100%) V (100%) A (100%) - - - P (100%) - 
T (100%) 
S (100%) 
6g 3 R (100%) L (100%) N (67%) S (67%) - - - 
P (67%) 
S (33%) - T (100%) 
6h 2 - V (100%) A (100%) - - - P (100%) - T (100%) 
6k 1 - V (100%) A (100%) - - - P (100%) - T (100%) 
6l 8 - V (100%) A (88%) T (13%) - - - P (100%) - T (100%)  
6m 3 - V (100%) S (100%) - - - T (100%) - S (100%) 
6n 2 - M (50%) V (50%) S (100%) - - - T (100%) - S (100%) 
  
000788244 
 
 
a RASs reported with ≥5% prevalence within each analyzed subtype population.  
b
 RASs detected with ≥15% abundance in patient virus sequence.  
c
 RASs carried by the majority of the subtype population (≥50% prevalence) are in bold. RASs held by a minority (<50%) of the subtype population are not in bold 
and are listed in order of prevalence. 
d
 Reference amino acid at RAS site based on GT1a H77 reference sequence is not associated with resistance. Any changes from this reference are shown.  
e
 Dash (-) indicates no change from reference and no minority substitutions detected in analysis. 
* Patient n represents all patients analyzed across all positions. Actual analyzed number may be lower depending upon position. 
 
 
  
6o 1 - L (100%) A (100%) - - - A (100%) - T (100%) 
6p 2 - V (100%) S (100%) - - - P (100%) A (100%) P (50%) T (100%) 
6q 4 - V (75%) M (50%) S (100%) - - - 
P (75%) 
L (25%) - T (100%) 
6r 1 - A (100%) A (100%) - - - P (100%) - T (100%) 
7 1 - L (100%) L (100%) - - - P (100%) - H (100%) 
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Table 5. NS5B RASs in HCV GT1-7 Subtypes  
 
 
  NS5B RAS POSITIONa,b,c 
Subtype Patients (n)* S96d N142 L159 E237 S282 C289 L320 V321 
1a 4268 -e - - - - - - - 
1b 2243 - N (96%) S (5%) 
L (92%) 
F (8%) - - - - - 
1c 3 - - - - - - - - 
1e 6 - - - - - - - - 
1g 2 - - - - - - - - 
1h 1 - - - - - - - - 
1l 3 - - - - - - - - 
2k-1b 6 - - - - - - - - 
2a 399 - - - - - M (96%) - - 
2b 869 - - - - - M (92%) I (9%) - - 
2c 65 - - - - - M (97%) - - 
2d 3 - - - - - M (100%) - - 
2e 2 - - - - - M (100%) - - 
2i 12 - - - - - M (100%) - - 
2j 2 - - - - - M (100%) - - 
2k 11 - - - - - M (91%) L (9% ) - 
V (91%) 
I (9%) 
2r 2 - - - - - M (100%) - - 
3a 2434 - - - - - F (100%) - - 
3b 27 - N (74%) S (22%) - - - F (100%) - - 
3g 7 - - - - - F (100%) - - 
3h 2 NA NA NA - - L (100%) - - 
3i 12 - - - - - F (100%) - - 
3k 4 NA NA NA H (50%) E (25%), L (25%) - F (100%) - - 
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4a 349 - - - E (81%) A (12%), G (6%) - F (99%) - - 
4b 3 - - - - - F (100%) - - 
4c 5 - - - E (80%) A (20%) - F (100%) - - 
4d 86 - - - - - F (100%) - - 
4f 4 - - - - - F (100%) - - 
4k 2 - - - - - F (100%) - - 
4l 14 - - - E (93%) G (7%) - F (100%) - - 
4m 2 NA NA NA - - F (100%) - - 
4n 11 - - - - - F (100%) - - 
4o 24 - - - - - F (100%) - - 
4r 8 - N (75%) S (25%) - - - F (100%) - 
I (75%) 
V (25%) 
4t 1 - - - - - F (100%) - - 
5a 76 - - - - - M (96%) - - 
6a 55 - - - N (100%) - M (96%) - - 
6d 2 NA NA NA H (100%) - L (100%) - - 
6e 23 - - - H (52%) R (43%) - L (100%) - - 
6f 1 - - - H (100%) - L (100%) - - 
6g 5 NA NA NA - - M (100%) - - 
6h 2 - - - Q (100%) - M (100%) - - 
6k 1 - - - R (100%) - L (100%) - - 
6l 8 - - - R (100%) - L (100%) - - 
6m 3 - - - H (100%) - M (100%) - - 
6n 2 - - - H (100%) - L (100%) - - 
6o 1 - - - H (100%) - L (100%) - - 
6p 2 - - - H (100%) - I (50%) L (50%), M (50%) - - 
6q 5 - - - H (100%) - L (100%) - - 
6r 1 NA NA NA - - L (100%) - - 
7 1 - - - C (100%) - - - - 
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a RASs reported with ≥5% prevalence within each analyzed subtype population.  
b
 RASs detected with ≥15% abundance in patient virus sequence.  
c
 RASs carried by the majority of the subtype population (≥50% prevalence) are in bold. RASs held by a minority (<50%) of the subtype population are not in bold 
and are listed in order of prevalence. 
d
 Reference amino acid at RAS site based on GT1a H77 reference sequence is not associated with resistance. Any changes from this reference are shown.  
e
 Dash (-) indicates no change from reference and no minority substitutions detected in analysis. 
* Patient n represents all patients analyzed across all positions. Actual analyzed number may be lower depending upon position. 
NA = not available; a partial sequence did not overlap the analyzed RAS position.
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